Search Results

• • 10 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Select Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.

  1

  Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.

  Authors:Michael A. Spinner and Ranjana H. AdvaniFrom:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 20224,333 words Article 2040LDiffuse large B-cell lymphoma [DLBCL], the most common subtype of non-Hodgkin lymphoma, is an aggressive and biologically heterogeneous disease. Risk stratification and treatment algorithms vary based on stage of disease...
• Select EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Belzutifan for Renal Cell Carcinoma.

  2

  EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Belzutifan for Renal Cell Carcinoma.

  From:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 2022886 words Article 1310LProduct Profile Drug name: Belzutifan [Welireg] Date of approval: August 13, 2021 Initial indication: For patients with von Hippel-Lindau [VHL] disease who need therapy for associated renal cell carcinoma [RCC],...
• Select Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer.

  3

  Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer.

  Author:Jun GongFrom:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 20221,064 words Article 1840LThe authors of this timely study evaluated the outcomes of neoadjuvant chemotherapy CNAC] in elderly patients C70 years or older] undergoing radical cystectomy CRQ for muscleinvasive bladder cancer CMIBQ. Using one of...
• Select Tripathy Details Importance of Both Clinical Research and Patient Advocacy: "If we can understand the mechanisms of resistance to be able to monitor [patients] in real time, then we will be able to turn many cases of cancer into chronic diseases.".

  4

  Tripathy Details Importance of Both Clinical Research and Patient Advocacy: "If we can understand the mechanisms of resistance to be able to monitor [patients] in real time, then we will be able to turn many cases of cancer into chronic diseases.".

  Author:Debu TripathyFrom:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 20222,438 words Interview 1280LWith the approval of trastuzumab (Herceptin) in the 1990's, targeted therapy became an option for treating patients with HER2-positive breast cancer. And as technology for systemic therapies evolve, new treatments...
• Select Looking Ahead: What's Next for Hematology/Oncology in 2022?

  5

  Looking Ahead: What's Next for Hematology/Oncology in 2022?

  Author:Julie M. VoseFrom:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 2022583 words Article 1550LWe are coming up on almost 2 years of treating our immunocompromised patients in hematology/oncology while trying to keep them safe from COVID-19 infections. At the same time, new treatments need to be studied in...
• Select Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations.

  6

  Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations.

  Authors:Madhuri Chengappa, Ronald S. Go, Ariela Marshall, and Thejaswi K. PoonachaFrom:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 20222,644 words Article 1650LBACKGROUND: While female representation in the National Comprehensive Cancer Network (NCCN] and European Society of Medical Oncology (ESMO] clinical practice guidelines (CPGs] has been studied to a limited degree, the...
• Select Strategies to Avoid Malpractice Suits.

  7

  Strategies to Avoid Malpractice Suits.

  From:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 2022487 words Article 1390LDespite the adage "to err is human," physicians who err on the job risk becoming the subject of medical malpractice lawsuits that can strongly inhibit their ability to practice. These lawsuits can define entire careers,...
• Select Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.

  8

  Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.

  Authors:Natasza Posielski, Hannah Koenig, On Ho, Christopher Porter, and John Paul FloresFrom:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 20224,706 words Article 1580LOBJECTIVES/INTRODUCTION: Neoadjuvant chemotherapy (NAC] prior to radical cystectomy (RC] for muscle-invasive bladder cancer (MIBC] is associated with survival benefit across patients of all ages, yet it is not offered to...
• Select Reviewed in ONCOLOGY[R]: Gender Representation on Guideline Panels.

  9

  Reviewed in ONCOLOGY[R]: Gender Representation on Guideline Panels.

  Author:Mike HennessyFrom:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 2022322 words Brief article 1650LAs we turn the page and enter a new year, we often reflect on the past 12 months while also looking forward to what's on the horizon. Equality in health care, for example, was brought to the fore in recent months due to...
• Select Remembering Michael J. Hennessy Sr.

  10

  Remembering Michael J. Hennessy Sr.

  Author:Michael J. HennessyFrom:Oncology (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 2022513 words Article 1370LFor many of our readers, this letter will be different than most. It is with deep sorrow we write this after the loss of the chairman and founder of MJH Life Sciences'", Michael J. Hennessy Sr. Those who knew him...